Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06414590 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Tebentafusp for Uveal Melanoma
A Phase 2 study of Locally Advanced Unresectable Uveal Melanoma, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT06414590 is a Phase 2 study of Locally Advanced Unresectable Uveal Melanoma that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 19 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06414590, a Phase 2 study of Locally Advanced Unresectable Uveal Melanoma, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial tests how well tebentafusp works to shrink tumors prior to primary treatment with surgery or radiation in patients with uveal (eye) melanoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Tebentafusp is a drug that binds to melanoma tumor cells as well as immune cells called T-cells. This binding causes an immune response against the melanoma cells, which leads to tumor cell death. Tebentafusp has been approved for the treatment of locally advanced and unresectable uveal melanoma. Giving tebentafusp before primary treatment with surgery or radiation may help shrink the tumor, prevent the disease from spreading, or reduce the likelihood that patients will require total eye removal (called enucleation).
Conditions Studied
Interventions
- DRUG Tebentafusp-Tebn
Study Locations (2)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
- Wills Eye Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2025-09-05 |
| Est. Completion | 2032-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06414590
The ClinicalTrials.gov registry entry for NCT06414590 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced Unresectable Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Tebentafusp-Tebn is the first listed.
NCT06414590 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06414590 about?
NCT06414590 is a clinical study titled "Neoadjuvant Tebentafusp for Uveal Melanoma". This phase II trial tests how well tebentafusp works to shrink tumors prior to primary treatment with surgery or radiation in patients with uveal (eye) melanoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Tebentafusp is a dr...
What is the current status of trial NCT06414590?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2025-09-05. Estimated completion is 2032-03.
What conditions does trial NCT06414590 study?
This clinical trial studies the following conditions: Locally Advanced Unresectable Uveal Melanoma.
What interventions are being tested in trial NCT06414590?
The interventions under investigation include: Tebentafusp-Tebn (DRUG).
Who is sponsoring clinical trial NCT06414590?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06414590 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.